Skip to main content
. 2015 Feb 25;24(13):1521–1535. doi: 10.1089/scd.2014.0588

FIG. 5.

FIG. 5.

Effect of VAV3 knockdown on paclitaxel (PTX)-resistant ovarian cancer cells. (A) Spheroid-forming assay. The number of spheroid formations decreased significantly after treatment of VAV3 siRNA (30% decrease compared with negative siRNA control). The size of the spheroids was also markedly reduced in VAV3 siRNA-treated SKpac cells compared with that of control and negative siRNA treatment. The graph represents the mean±standard error of triplicate experiments (*P<0.001). (B) Colony-forming assay. VAV3 knockdown cells were seeded at 300 cells per well and grown for 14 days. The number of colonies of SKpac cells treated with VAV3 siRNA decreased by 41% compared with the cells treated with negative siRNA. The graph represents the mean±standard error of triplicate experiments (*P<0.001). (C) MTT assay. Cell viability was assessed by the MTT assay after inhibition of VAV3 by siRNA treatment. Cell viability decreased by 25% and 18% (*P<0.05) at 24 and 48 h, respectively, in SKpac cells treated with VAV3 siRNA compared with the negative siRNA control. With VAV3 siRNA and 40 nM PTX treatment, the number of SKpac cells decreased by 27% (*P<0.05) and 16% at 24 and 48 h compared with PTX+negative siRNA treatment. The graph represents the mean±standard error of triplicate experiments.